课题基金 / 基金详情

卵巣癌の制癌剤抵抗性に関与するアポトーシスシグナルの分子生物学的解析-遺伝子治療の分子標的の確立をめざして-

卵巣癌の制癌剤抵抗性に関与するアポトーシスシグナルの分子生物学的解析-遺伝子治療の分子標的の確立をめざして-
卵巢癌抗癌药物耐药性中涉及的细胞凋亡信号的分子生物学分析 - 旨在建立基因治疗的分子靶标 -
批准号:
11671613
负责人:
MANDAI Masaki
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000

项目摘要

项目成果

MANDAI Masaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this study is to clarify the association between the intracellular apoptotic signaling and the cytotoxic/therapeutic effect of cisplatin in ovarian cancer. Then, according to the findings obtained, we tried to develop a new strategy to manage cisplatin-resistant ovarian cancer.Firstly, the influence of apoptosis on the effect of cisplatin is examined. Treatment with cisplatin in cisplatin-sensitive ovarian cancer cell line A2780 markedly induced apoptosis, which was detected both by morphological examination as well as quantification of apoptosis using cell death ELISA method or measurement of caspase 3 activity. In contrast, cisplatin in the same dose did not induce significant apoptosis in cisplatin-resistant SK-OV-3 cell line. In addition, an inhibitor of caspase 3, Ac-DEVD-CHO, reduced the cytotoxity of cisplatin, suggesting that the effect of cisplatin is closely linked to the induction of apoptosis in ovarian cancer cells.Secondly, the role of pro-apoptotic Bax p … More rotein in the development of cisplatin-resistance of ovarian cancer was investigated. Immunohistochemical analysis revealed that decreased expression of Bax protein correlated with poor prognosis of patient with ovarian cancer. In vitro, Bax expression was attenuated in cisplatin-resistant ovarian cancers, A2780/cDDP and SK-OV-3, compared with cisplatin sensitive A2780. These findings suggest that the disturbance in pro-apoptotic signaling through Bax play an inportant role in the development of cisplatin-resistance. Accordingly, we tried to induce Bax protein in ovarian cancer cells using recombinant adenovirus which highly express the Bax protein. The pro-apoptotic effect of Bax induction was similarly intensive either in A2780 or A2780/cDDP, while it was minimum in SK-OV-3. Preliminarily, adenovirus-mediated transfer of the Bax gene into human ovarian xenografts showed suppressive effect on tumor growth. Therefore, adenovirus-mediated introduction of Bax may be a useful tool to manage a part of cisplatin-resistant ovarian cancer.Thirdly, the influence of gonadotropins, luteinizing hormone (LH) and human chorionic gonadotropin (hCG), on the apoptosis of ovarian cancer was examined. More than a half of ovarian cancer specimens expressed LH/hCG receptor. hCG treatment markedly reduced cisplatin-induced apoptosis in LH/hCG receptor-positive ovarian cancer cell line, OVCAR-3, and induced insulin-like growth factor 1 (IGF-1 ) expression. IGF-1 also inhibited cisplatin-induced apoptosis and a neutralizing antibody to IGF-1 receptor restored apoptosis in OVCAR-3, suggesting that IGF-1 mediates anti-apoptotic signaling from hCG.Wortmannin, an inhibitor of phosphatidyl inositol 3 kinase (PI3K), blocked the anti-apoptotic effect of IGF-1 to restore the cisplatin-induced apoptosis. This indicates that specific phosphorylation signal is related to cisplatin-sensitivity/resistance of ovarian cancer.In conclusion, both the intrinsic disturbance of intracellular apoptosis signal including Bax and the presence of anti-apoptotic extrinsic factors such as IGF-1 may cause the resistance to chemotherapy in ovarian cancer. Consequently, to regulate apoptosis-related gene and to facilitate apoptosis by the methods including adenovirus-mediated gene therapy may be a hopeful strategy to overcome drug-resistance. Less
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
Masaki MANDAI: "A Novel Approach to Modurate the Expression of Apoptosis-related Genes as a Treatment Strategy of Chemo-resistant Ovarian Cancer"ACTA OBST GYNAEC JPN. Vol.51. 575-585 (1999)
Masaki MANDAI:“调节细胞凋亡相关基因表达的新方法作为化疗耐药性卵巢癌的治疗策略”ACTA OBST GYNAEC JPN。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
鶴田優子: "婦人科癌の浸潤・転移とその臨床「卵巣癌の転移にかかわる遺伝子」"産婦人科の実際. 49(6). 765-774 (2000)
Yuko Tsuruta:“妇科癌症的侵袭和转移及其临床实践``与卵巢癌转移相关的基因。妇产科实践。49(6)。765-774(2000)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
万代昌紀: "卵巣癌細胞のアポトーシス抑制に関与する遺伝子群を標的とした新しい癌化学療法の基礎的研究"日本産科婦人科学会雑誌. 51. 575-585 (1999)
Masanori Bandai:“针对参与抑制卵巢癌细胞凋亡的基因的新型癌症化疗的基础研究”日本妇产科学会杂志 51. 575-585 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
万代昌紀: "がん治療のあゆみ 第19巻"(財)がん集学的治療研究財団. 8 (2000)
万代正德:《癌症治疗史第19卷》癌症多学科治疗研究基金会8(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
17
    Development of an interface to refer OMICS information into clinic
    • 批准号:
      25670703
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      MANDAI Masaki
    • 依托单位:
    immune environment in the peritoneal cavity and development of novel immune therapy in ovarian cancer
    • 批准号:
      21592130
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2009
    • 负责人:
      MANDAI Masaki
    • 依托单位:
    Activated local immunity by chemokine CCL19-transfected embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer
    • 批准号:
      19591932
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      MANDAI Masaki
    • 依托单位:
    enhancement of anti-tumor immunity in dendritic cell therapy toward gynecological malignancies
    • 批准号:
      17591732
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.92万
    • 财政年份:
      2005
    • 负责人:
      MANDAI Masaki
    • 依托单位:
    国内基金
    海外基金
    Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
    • 批准号:
      LBY21H010001
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2020
    • 负责人:
      郑绪阳
    • 依托单位:
    去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
    • 批准号:
      31970691
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2019
    • 负责人:
      张胜萍
    • 依托单位:
    TM9SF4调控非小细胞肺癌细胞凋亡机制研究
    • 批准号:
      31900527
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2019
    • 负责人:
      孙磊
    • 依托单位:
    基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
    • 批准号:
      81703335
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      卫高菲
    • 依托单位: